CardioKinetix, a Menlo Park, Calif.-based medical device company, has completed the $23 million second-tranche of its Series E financing, bringing the total round to $48 million. Panorama Capital is the company’s newest investor. It joins previous investors U.S. Venture Partners, JPMorgan Partners, New Leaf Venture Partners, SV Life Sciences, H&Q Healthcare Investors, and H&Q Life Sciences Investors.

Versartis, an emerging biotechnology company has completed a $25 million Series C financing lead by new investor Aisling Capital. Also participating in the round were existing investors Index Ventures, New Leaf Venture Partners and Advent Venture Partners‘ Advent Life Sciences fund.

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

Awarepoint Corp., the real-time location system services provider for healthcare clients, has added $14 million in funding. Heritage Group led the round and was joined by Kleiner Perkins Caufield & Byers, Cardinal Partners, Venrock, Jafco Ventures, Avalon Ventures, New Leaf Venture Partners and Top Tier Capital Partners. PRESS RELEASE: Awarepoint Raises $14 Million in Additional [...]

Medical device company CardioKinetix has apointed Maria Sainz as president and chief executive officer. Recently Sainz served as general manager of Stryker Neurovascular, which acquired Concentric Medical in October 2011 under her leadership as president and CEO. CardioKinetix is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, Panorama Capital, and H&Q [...]

Truveris Inc. has raised $10 million in Series B financing, the company announced Thursday. New Leaf Venture Partners led the round, which also included participation from Tribeca Venture Partners, New Atlantic Ventures and First Round Capital. Formed in 2009, Truveris makes software designed to provide transparency and cost containment in the prescriptions claims process. PRESS [...]

Publicly traded Biogen Idec is buying venture-backed Stromedix Inc. Under the terms of the deal, Biogen Idec will make an upfront cash payment of $75 million and additional payments of up to $487.5 million based on certain milestones. Stromedix’s investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and [...]

CardioKinetix, a medical device company developing transcatheter implants, has raised $44 million in a two-tranche Series E financing. New investors SV Life Sciences and New Leaf Venture Partners led the round, which included return backers including U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors. The company’s device, dubbed Parachute, is implanted into the left ventricle of the heart in a simple catheter lab procedure and is intended to treat patients with heart failure resulting from a myocardial infarction or heart attack.

Neuronetics, the Pennsylvania-based maker of non-invasive, non-systemic treatments for depression, completed a $30 million Series E financing. New investors Polaris Venture Partners and Pfizer Venture Investments led the round and were joined by previous investors Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures, and Onset Ventures.

Lexington, Mass.-based Synageva BioPharma Corp. has closed on $25 million in new financing. No details of the financing were disclosed. Synageva has raised more than $70 million in the last two years from investors including New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson and Four Partners.